Accueil > Publications
Études de phase III
Données de la Semaine 96 des études HAWK et HARRIER
Dugel PU, Singh RP, Koh A, Ogura Y, Weissgerber G, et al. HAWK and HARRIER: 96-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-related Macular Degeneration. Ophthalmology 2020; sous presse.
Données de la Semaine 48 des études HAWK et HARRIER
Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, et al. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology 2020;127:72–84.
Études de phase II
Dugel PU, Jaffe GJ, Sallstig P, Warburton J, Weichselberger A, et al. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial. Ophthalmology 2017;124:1296–304.
Holz FG, Dugel PU, Weissgerber G, Hamilton R, Silva R, et al. Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study. Ophthalmology 2016;123:1080–9.
Rapports du Comité d’examen de la sécurité
Safety Review Committee. Novartis-Appointed Safety Review Committee Reports Initial Brolucizumab Findings. Publié en juin 2020
Analyse post-hoc de Hawk et Harrier
Monés J, Srivastava SK, Jaffe GJ, Tadayoni R, Albini TA, et al. Risk of inflammation, retinal vasculitis and retinal occlusion-related events with brolucizumab: post-hoc review of HAWK and HARRIER. Ophthalmology 2020; in press